6/1/2020 8:09:00 AM
Diffusion Regains Compliance With NASDAQ Minimum Bid Price Requirement
5/26/2020 8:06:39 AM
Diffusion Receives Accelerated Response From FDA To PIND Meeting Request
4/1/2020 8:15:59 AM
Diffusion Evaluates Trans Sodium Crocetinate Against ARDS In COVID-19 Patients
2/7/2020 8:38:43 AM
Diffusion Pharmaceuticals Secures European Patent Related Compositions Of TSC
7/23/2019 8:43:35 AM
Diffusion Reports Favorable Safety Data For Dose-Escalation Run-in Of Phase 3 INTACT Study
12/17/2018 9:57:16 AM
US Patent Office Awards Diffusion Rights For Use Of TSC In Conjunction With Only FDA-Approved Stroke Therapeutic
11/14/2018 9:06:44 AM
Diffusion Pharma Q3 Loss/shr $0.13 Vs. EPS $0.20 Prior Year
9/12/2018 9:05:01 AM
FDA Oks Start Of Innovative On-Ambulance Phase 2 Trial For Treatment Of Acute Stroke By Diffusion Pharma
8/13/2018 8:34:57 AM
Diffusion Pharma H1 Net Cash Used In Operating Activities $5.8 Mln Vs $6.2 Mln Last Year
6/12/2018 8:43:54 AM
Diffusion Pharma Announces Validation Of European Patent For Oral Formulations Of TSC
2/1/2018 8:15:43 AM
Diffusion Announces Allowances Of Two U.S. Patent Applications